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Over the last decades, thyroid hormonemetabolites (THMs) receivedmarked attention as
it has been demonstrated that they are bioactive compounds. Their concentrations were
determined by immunoassay or mass-spectrometrymethods. Among thosemetabolites,
3,5-diiodothyronine (3,5-T2), occurs at low nanomolar concentrations in human serum,
but might reach tissue concentrations similar to those of T4 and T3, at least based on
data from rodent models. However, the immunoassay-based measurements in human
sera revealed remarkable variations depending on antibodies used in the assays and
thus need to be interpreted with caution. In clinical experimental approaches in euthyroid
volunteers and hypothyroid patients using the immunoassay as the analytical tool no
evidence of formation of 3,5-T2 from its putative precursors T4 or T3 was found, nor was
any support found for the assumption that 3,5-T2 might represent a direct precursor for
serum 3-T1-AM generated by combined deiodination and decarboxylation from 3,5-T2,
as previously documented for mouse intestinal mucosa. We hypothesized that lowered
endogenous production of 3,5-T2 in patients requiring T4 replacement therapy after
thyroidectomy or for treatment of autoimmune thyroid disease, compared to production
of 3,5-T2 in individuals with intact thyroid glands might contribute to the discontent seen
in a subset of patients with this therapeutic regimen. So far, our observations do not
support this assumption. However, the unexpected association between high serum
3,5-T2 and elevated urinary concentrations of metabolites related to coffee consumption
requires further studies for an explanation. Elevated 3,5-T2 serum concentrations were
found in several situations including impaired renal function, chronic dialysis, sepsis,
non-survival in the ICU as well as post-operative atrial fibrillation (POAF) in studies
using a monoclonal antibody-based chemoluminescence immunoassay. Pilot analysis of
human sera using LC-linear-ion-trap-mass-spectrometry yielded 3,5-T2 concentrations
below the limit of quantification in the majority of cases, thus the divergent results
of both methods need to be reconciliated by further studies. Although positive anti-
steatotic effects have been observed in rodent models, use of 3,5-T2 as a muscle
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anabolic, slimming or fitness drug, easily obtained without medical prescription, must
be advised against, considering its potency in suppressing the HPT axis and causing
adverse cardiac side effects. 3,5-T2 escapes regular detection by commercially available
clinical routine assays used for thyroid function tests, which may be seriously disrupted
in individuals self-administering 3,5-T2 obtained over-the counter or from other sources.
Keywords: thyroid hormone, 3,5-diiodothyronine, hypothyroidism, metabolome, anti-steatotic action, coffee
metabolites, chemoluminescence immunoassay, deiodinase
GRAPHICAL ABSTRACT | Structural formula of the “Janus-faced” THM 3,5-diiodo-L-thyronine (left), which has the same 3,5-iodine substitution pattern as its
putative precursors L-T4 and L-T3 at the tyrosyl-ring, but lacks the iodine substitution in 3
′
-position of the phenolic ring which is essential for binding classical T3
-receptors and conveying canonical and non-canonical thyromimetic effects. The roman god Janus symbolized “duality” and “jani” were ceremonial gateways in
ancient Rome typically used for symbolically auspicious entrances or exits. Janus-face (right) source: This image comes from the 4th edition of Meyers
Konversationslexikon (1885–90). The copyrights have expired and this image is in the public domain. Wikimedia, Meyers_b9_s0153_b1.png.
HYPOTHESES AND THEORY
a. 3,5-T2 is an endogenous metabolite of thyroid hormones T4
and T3
b. 3,5-T2 might represent the precursor of 3-iodothyronamine
c. 3,5-T2 acts like T3 via canonical activation of T3 receptors
albeit with lower potency
d. 3,5-T2 exerts actions distinct from those of
thyromimetically active T3
i) via mitochondrial targets
ii) by its intrahepatic accumulation
iii) by its intracrine mode of action
e. 3,5-T2 formation and action might be altered in patients on
T4 replacement therapy and causes adverse effects if abused.
INTRODUCTION
Endogenous Thyroid Hormones and Their
Metabolites
A century of thyroxine research has led to the commonly
held opinion in the thyroid hormone community that 3,3′,5,5′-
tetraiodo-L-thyronine (L-Thyroxine, L-T4), which is solely
produced by the thyroid gland, serves as a prohormone while
T3 (3,3′5-triiodo-L-thyronine), in part secreted by the thyroid
gland, is mainly generated in various extra-thyroidal tissues by
either type 1 or type 2 deiodinase (DIO1, DIO2) selenoenzymes
(1–3). T3 exerts the majority of known thyroid hormone (TH)
effects at the tissue and cellular level, including hypothalamic
and pituitary negative feedback regulation of the hypothalamus-
pituitary-thyroid-periphery (HPTP) axis (4–6). Over the last
years, some evidence has been presented that T4 also binds
to cell membrane-located ανβ3 integrin receptors which exert
rapid signaling via various kinase and intracellular pathways,
especially in tumor cells and stem cells (7, 8). The T4 metabolite
Tetrac, a deaminated side chain metabolite, present in human
serum at concentrations similar to those of T3 (3, 9) antagonizes
such T4 (and also T3) actions at the integrin receptor signaling.
However, whether this has physiological relevance beyond these
pharmacological approaches, mainly tested so far in cancer or
stem cells, remains to be demonstrated. A further metabolite
of T4 found in human serum, 3,3′,5′-triiodothyronine (reverse
T3, rT3) has been studied over the last four decades because its
production by the type 3 deiodinase (DIO3), also a selenoprotein,
is increased under conditions when T3 production by DIO1
is impaired (3, 9) as well as during development in many
tissues, when DIO2 activity is decreased (10). As rT3 is also
degraded by DIO1, such conditions of high rT3 and low T3 (and
T4) serum concentrations, summarized under the term “non-
thyroidal critical illness” or “low T3 syndrome,” have caught
the attention of clinicians attempting to use this constellation
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as a diagnostic or predictive readout. Up to now, no clear
demonstration of rT3 function has been observed apart from its
role during glial cell-mediated neuronal guidance in mammalian
brain development (11). The initial hypothesis that rT3 might
act as potent inhibitor of DIO1 or DIO2 during T3 formation
(12, 13) could not be supported by in vivo experiments due to
its short half-life and insufficient local concentrations (14). These
observations did not support the hypothesis of rT3 acting as
an autonomous regulator of extrathyroidal T3 formation under
(patho-)physiological conditions.
3,5-T2 Is a Further Endogenous TH
Metabolite With Thyromimetic Potency
The TH metabolite 3,5-T2, possibly formed from its precursor
T3 (Figure 1), has recently attracted great interest for several
reasons (3, 9, 15). 3,5-T2 has been considered the main
biological active metabolite of T3, formed via further phenolic
ring deiodination from T3 (Figure 1). The TH metabolite 3,5-
T2 is found in blood and at even higher concentrations in
several tissues. Various groups have demonstrated that 3,5-
T2, in addition to its thyromimetic action at the classical T3
receptors at high concentrations, exerts rapid direct effects
on mitochondria (6, 16–19), which might be beneficial in
terms of stimulation of oxygen consumption, increased hepatic,
and muscular lipid metabolism—all of these effects appear as
potentially favorable in global attempts to combat steatosis in
liver and other tissues.
Therefore, we intended to test several hypotheses using
clinical experimental data, animal experiments, and cell culture
approaches as well as recently developed novel analytical tools
such as the sensitive chemoluminescence immunoassay (CLIA),
highly specific for 3,5-T2 detection in human serum (20). We
aimed to test the hypotheses that
i) 3,5-T2 is formed from T4 and T3 as its precursors via
deiodinase reaction,
ii) 3,5-T2 circulates in human serum, and that various
pathophysiological as well as experimental conditions lead to
alterations in 3,5-T2 serum concentrations.
iii) Furthermore, that effects of administration of physiological
and pharmacological doses of 3,5-T2 in mouse models will
provide information on its potential thyromimetic activity as
well as for its potentially beneficial antisteatotic action.
iv) Moreover, analyses using various in vitro cellular models
might convey an insight into postulated mechanism(s) of
action of 3,5-T2 at the level of gene expression and/or
mitochondrial energy metabolism.
v) 3,5-T2 causes adverse effects if abused and/or overdosed.
This series of clinical, translational and basic science studies
testing these options resulted in a complex picture of various
actions of 3,5-T2. The outcome was variable depending on
concentrations applied, experimental models used, and analytical
tools applied so far. 3,5-T2 turned out to be an ambiguous,
Janus-type endogenous thyroid hormonemetabolite (THM)with
beneficial and adverse biological effects. Analytical tools available,
cannot yet dispel previously reported controversies regarding its
FIGURE 1 | Postulated pathway of biosynthesis of 3,5-T2 from its putative
precursors T4 and T3. The figure shows the structural formulas of L-T4, the
prohormone, synthetized, and secreted by the thyroid gland, and its
5′-deiodination product L-T3, which is secreted in part by the thyroid gland
(ca. 80%) or generated in extrathyroidal tissues by the two selenoenzyme
5-deiodinase type 1 or type 2, which both remove the 5′-iodine atom of L-T4
in a reductive two-substrate reaction with a so far unknown physiological
cofactor. Indirect evidence mainly from in vivo experiments in rodents suggests
that 3,5-T2, a physiologically active endogenous thyroid hormone metabolite,
is formed by a further 3′-deiodination reaction also catalyze by these (one of
these) two deiodinase enzymes.
baseline concentrations in human serum and the variations in
concentration caused by pathophysiological states.
Currently, the thyroid community and patients discuss
why a fraction of patients on established L-T4 replacement
therapy, due to thyroidectomy or autoimmune thyroid disease,
are subjectively discontent with this therapeutic regimen
compared to individuals with intact thyroid, albeit their thyroid
function test are in the reference range. We hypothesize
that endogenous production of 3,5-T2 in some patients
dependent on oral L-T4 might be less than that in individuals
whose intact thyroid is the source of T4, and thus an
inadequate 3,5-T2 concentration might contribute to this
discontent based on its distinct thyromimetic activity compared
to T3.
3,5-T2 CONCENTRATIONS IN HUMAN
SERUM
Immunoassays for 3,5-T2 Using Polyclonal
Antisera Reveal Divergent Concentrations
Following the detection of the thyromimetically active T3
in human serum and its production from T4 in athyreotic
humans supplemented with L-thyroxine (21, 22), attempts
were also made to quantify concentration of 3,5-T2 in human
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TABLE 1 | Serum concentrations reported for 3,5-T2 and 3,3′-T2 over the last 4 decades using different analytical techniques (immunoassay formats, mass
spectrometry).
References Assay type Serum 3,5-T2 (pM) Serum 3,3′-T2 (pM) Species
Richards et al. (23); Richards et al. (24); Richards et al. (25) LC/MS-MS <5 41 ± 8 Human
Lehmphul et al. (20) CLIA 290 ± 10 – Human
Gu et al. (26) LC/MS-MS – 52 ± 16 Human
Jonklaas et al. (27) LC/MS-MS – 12.2–28.2 Human
Moreno et al. (28); Pinna et al. (29) RIA 4.6 ± 0.4 68 ± 21 Rat
Pinna et al. (30) RIA 16.3 ± 6.4 – Human
Engler and Burger (31) RIA 7.6 ± 3.4 – Human
Jaedig and Faber (32) RIA 70 42 Human
Kirkegaard et al. (33) RIA 105 ± 51 36 ± 15 Human
Nishikawa et al. (34) RIA 196 ± 36 67 ± 36 Human
Pangaro et al. (35) RIA 82 ± 4 – Human
Maciel et al. (36) RIA 139 ± 67 – Human
Meinhold and Schürnbrand (37) RIA 100 – Human
Bold values give mean serum concentrations reported by authors.
serum and tissues. Most of these studies were feasible after
the development of specific radioimmunoassays, based on
poly- or monoclonal antibodies in the Seventies of the last
century, and supported extrathyroidal formation of 3,5-T2,
which had been previously demonstrated using radioisotope-
labeled TH in humans, experimental animal models, and in
vitro systems [see recent reviews: (3, 9)]. Initially, various
groups attempted to quantify 3,5-T2 under physiological and
pharmacological conditions and in various disease states, mainly
using radioimmunoassays based on specific polyclonal antibodies
generated against 3,5-T2 conjugates in various animal models.
The assays developed during the 1980s were sensitive enough
to detect 3,5-T2 in unextracted serum samples directly, as
summarized in Table 1. In contrast to rather precise and
narrow concentration ranges detected for total T4, total T3,
and total rT3 in human serum, the concentration ranges
for 3,5-T2 showed remarkable differences between various
assays used, exceeding more than one order of magnitude
from 4 to almost 200 pM/L. This is in sharp contrast to
concentrations reported for the other THM formed from either
T3 via 5-deiodination at the tyrosyl- ring (3,3′-T2), or from
rT3 generated by phenolic ring deiodinaton (3,3′-T2) or the
rare T2 metabolite 3′,5′-T2 generated from rT3 via tyrosyl-
ring deiodination. Reported serum concentrations covered a
very narrow concentration range between 36 and 68 pM for
3,3′-T2 (see Table 1) (23–29, 32–34). Authors discussed this
point, but no clear explanation or hypothesis was put forward
to explain this peculiar observation atypical for the usually
highly precise immunoassays for THM. The variable results
might be explained by technical difficulties in reproducibly
synthesizing and purifying tyrosyl-ring mono-labeled tracers
required for these competitive immunoassays, as it turned out
to be very difficult to avoid additional radioactive labeling of
the phenolic ring of 3,5-T2, which would yield a T3-analog
tracer. Only complex synthesis procedures different from the
typical Chloramine T labeling protocols used for T3, rT3, or
T4 yielded clean, radioactive tracers solely mono-labeled at the
tyrosyl-ring (38). Thus, reports on serum 3,5-T2 concentrations
determined by immunoassay methods need to be interpreted
with caution.
A similar problem exists also with respect to the purity
of 3,5-T2 standards used in these immunoassays, as
commercial preparations available now and in the past
frequently were significantly contaminated with T3 in
concentrations high enough to provide interference by
T3 serum concentrations, which are typically an order
of magnitude higher than those of 3,5-T2 in the 3 nM
concentration range.
A second difficulty still not clarified is the possibility
of a distinct binding of 3,5-T2 to (yet unknown) serum
distributor or transporter proteins, in comparison to T3
and T4 which are known to preferentially bind to the
classical thyroid hormone distributor proteins thyroxine-binding
globulin (TBG), transthyretin (TTR), and albumin. If residual
binding to any serum distributor protein for 3,5-T2 would
not be eliminated by incubation conditions or additives
releasing 3,5-T2 from this binding, the assumptions of adequate
equilibrium competition during incubation time and separation
of free ligands from those bound to the antibodies would
be compromised. Irrespective of these difficulties, various
research groups set out to analyze 3,5-T2 concentrations in
human serum in reference populations and individuals with
altered thyroid function as well as disease states, but no
uniform picture emerged and even observations of concentration
changes in clinical hyperthyroidism vs. hypothyroidism were
not uniform. Of interest was the observation that tissue
levels of 3,5-T2, for example in the rat brain, were much
higher than expected from serum concentrations and reached
values in the range of those of T4 and T3, as clearly
shown by Pinna et al. (29), who also observed changes
in 3,5-T2 concentrations of various rat brain regions after
administration of drugs used in neurology and psychiatry.
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Similarly, a notable hepatic accumulation of 3,5-T2 was
observed after administration of exogenous 3,5-T2 in a
mouse model (39) suggesting a role as a tissue-resident
“intracrine” hormone.
A Chemoluminescence Assay Based on
Monoclonal Antibodies Detects 3,5-T2
Serum Concentrations Not Directly
Related to Classical Parameters of Thyroid
Hormone Status
We set out to develop a monoclonal antibody-based CLIA, which
allows detection of 3,5-T2 in human serum at low concentrations
and under various pathophysiological conditions. Figure 2
illustrates the assay principle used (20, 40). Monoclonal
antibodies recognizing 3,5-T2 with high specificity and very
low cross-reactivity to other THM present in human serum
were incubated in a micro-titer plate assay format, wells
were coated with goat anti-mouse Fc antibody, and serum
containing 3,5-T2. After incubation and various washing steps,
horseradish peroxidase labeled 3,5-T2 competed with serum
3,5-T2 for binding to the anti-3,5-T2 monoclonal antibodies,
and after equilibration of this competitive arrangement,
chemiluminescence substrate was added to produce light
and quantifying HRP labeled 3,5-T2 tracer vs. endogenous
3,5-T2. Using this assay, validated according to state-of-the-
art technology with respect to assay stability, specificity, and
reproducibility, we detected serum 3,5-T2 concentration in
reference populations around 290 pM. Application of this
immunoassay to analyze 3,5-T2 concentrations under various
clinical conditions yielded unexpected results. First of all, 3,5-T2
concentrations in hypothyroid or hyperthyroid patients were
not different from those of the reference population, while
total T4 and T3 showed expected changes. We did not observe
FIGURE 2 | Assay principle used for the development of a monoclonal
antibody-based chemoluminescence immunoassay (CLIA). This method
allows to detect 3,5-T2 in human serum at low concentrations and under
various pathophysiological conditions (20, 40). HRP, horse-radish peroxidase;
mAB, monoclonal antibody; Fc Ab, Fc-fragment of a goat antibody
recognizing mouse mAb.
gender- or age-dependent variations, nor were concentrations
correlated with BMI. However, thyroidectomized patients
(after thyroid cancer diagnosis) showed slightly elevated serum
concentrations compared to the healthy reference population
(20), an observation to be confirmed by LC-LIT-MS/MS/MS
(LC-LIT-MS3) analysis. Patients with post-operative atrial
fibrillation (POAF) also had higher 3,5-T2 concentration than
a similar group of cardiology patients without POAF (41).
Of interest was the observation that, in a group of intensive
care unit (ICU) patients, non-survivors had significantly
higher 3,5-T2 concentrations than those who survived (42).
This was unexpected considering the low T3 concentrations
in those patients in context of the hypothesis that 3,5-T2
would be a direct product of T3 and potentially lowered
under conditions of decreased DIO1 (or DIO2) activity.
Even more surprising was the observation of remarkable
changes of 3,5-T2 concentrations, which were increased by
more than an order of magnitude in patients on pre-dialysis
compared to post-dialysis, with demonstration of even lower
concentrations in healthy controls (20). Figure 3 indicates
this remarkable concentration range and increase in 3,5-T2
concentrations, which, with respect to the amplitude observed,
is much higher than reported for any of the changes in T4,
T3, rT3, or 3,3′-T2 concentrations so far. This data and the
observation in ICU patients would be compatible with the
hypothesis that impaired renal elimination of 3,5-T2 leads
to its accumulation in serum or, alternatively, impaired renal
function might contribute to elevated 3,5-T2 production.
Such hypotheses need to be tested in appropriate prospective
studies. Still those observation based on CLIA analysis of
serum concentrations of 3,5-T2 require confirmation by
LC-LIT-MS3 analysis.
During our attempts to establish a reference range for 3,5-
T2 in a healthy population, we analyzed 3,5-T2 concentrations
in a subset of the population-based Study of Health in
FIGURE 3 | Elevated 3,5-T2 concentrations in serum of dialysis patients. (A)
Decrease in serum 3,5-T2 concentrations after dialysis, but still elevated
compared to healthy controls (*p < 0.05; **p < 0.01; ***P < 0.001). (B)
Comparison pre vs. post dialysis; paired t-test, Wilcoxon signed rank test
(Gaussian approximation) (***P < 0.001) (43).
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FIGURE 4 | Serum 3,5-T2 concentration and multifluid (urine and plasma) metabolomics in healthy individuals of the SHIP-Trend cohort. (Upper) P-values (y-axis) for
plasma metabolites (x-axis) after correction for multiple testing (false discovery rate—FDR) comparing participants with low serum 3,5-diiodothyronine (3,5-T2)
concentrations (<0.20 nM) with participants with high serum 3,5-T2 concentrations (>0.33 nM). Values have been transformed by –log10 to ease visualization of small
values. (Upper right) Opposing FDR-values for the same comparison for metabolites measured in plasma (y-axis) and urine (x-axis). (Left) Similar to upper panel but
showing the results for metabolites measured in urine only. Darker colors indicate metabolites meeting the threshold for statistical significance (FDR < 0.05) and red
indicates metabolites consistently associated in both fluids. Inset: Predicted least-square means with 95%-CIs from linear regression models for four metabolites
selected across the three approximately equally-sized groups of participants divided according to serum 3,5-T2 concentrations (44). All p-values were derived from a
linear regression model treating serum 3,5-T2 concentrations as categorical exposure and metabolites as outcome, controlling for age, sex, waist circumference as
well as serum thyroxine and thyrotropin concentrations. Blue—plasma and orange—urine.
Pomerania (SHIP-Trend) including 761 euthyroid participants.
The analysis comprised associations with various anthropometric
and clinically relevant parameters. Surprisingly, one third of the
study population had 3,5-T2 serum concentrations determined
by CLIA below the limit of quantification but above the
limit of detection, yielding a median serum concentration of
0.24 nM with right-skewed distribution. Associations of the 3,5-
T2 concentrations with various clinical chemistry parameters
were moderate. Of special interest was, similar to the previous
studies, the lack of a clear association with serum T4 and/or
T3 concentrations (44, 45). In a follow-up study of the same
cohort, 3,5-T2 serum concentrations were analyzed with respect
to urine metabolites analyzed by 1H-NMR spectroscopy (45–
48). Again, very few individuals had remarkably elevated 3,5-
T2 serum concentrations that might be suggestive of underlying
disease, although health status could not be traced back due to the
population-based study using anonymized sera. However, 3,5-T2
serum concentrations were remarkably positively associated with
various urine metabolites. More detailed metabolome analyses
revealed that these metabolites represent a “signature of coffee
consumers.” Among these urinary metabolites are trigonelline,
pyroglutamate, and hippurate. This observation is the first one
to link a THM to coffee consumption, and so far, no clear-
cut hypothesis has been tested to challenge a potential causal
relationship (45, 46). However, indirect evidence might support
the assumption that hepatic accumulation of 3,5-T2 (see below)
may alter hepatic (and/or renal) metabolism of components
consumed with (caffeinated and decaffeinated) coffee and thus
even might provide a link between beneficial antisteatotic
effects ascribed to 3,5-T2 and also to coffee consumption
(44–48) (Figure 4). Table 2 summarizes the observations made
in various pathophysiological states with respect to altered
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3,5-T2 concentration in human serum, as determined by the
monoclonal antibody-based CLIA.
BIOSYNTHESIS−3,5-T2 MAY NOT BE
GENERATED DIRECTLY FROM ITS
PUTATIVE PRECURSORS T4 AND/OR T3 IN
HUMANS
The discovery and demonstration of sequential mono-
deiodination pathways catalyzed by the three deiodinase
isoenzymes using tetra, tri-, di-, and mono-iodinated
iodothyronines as substrates has led to the assumption that
3,5-T2 formation in vivo occurs via 5′-deiodination of T3
catalyzed by either DIO1 or DIO2, while not much evidence
was available that 3,5-T2 would be a direct secretion product
from iodinated thyroglobulin. The existence of 3,5-T2 in
thyroglobulin has not been clearly demonstrated (49, 50)
and appears biochemically improbable considering that TPO
catalyzes coupling of mono- and/or di-iodinated tyrosine
residues to yield either T4 or T3, while no such coupling was
observed between diiodotyrosine and iodine-free tyrosine in
reports available. Formation of iodothyronines outside of the
thyroid gland has not been reported in humans or mammalian
organisms while various aquatic life forms synthesize T4 without
presenting the highly evolved follicular structure of thyroid
glands in vertebrates (51). Circumstantial evidence using the
DIO1 inhibitor PTU in isolated rat mitochondria or perfused
rat liver led to the assumption that 3,5-T2 is a logical deiodinase
product of T3 (16, 52), but various attempts to demonstrate
such a reaction in vitro failed to support this hypothesis. In
contrast, in vivo data from experimental animal models and
human studies, where PTU has been administered, resulted in
lower 3,5-T2 concentrations compared to appropriate controls.
However, these studies were also based on immunoassay
serum analytics.
In the light of marked variations of serum concentrations of
3,5-T2 in humans as determined by the monoclonal antibody-
based CLIA, we set out to test whether 3,5-T2 is formed in
vivo in humans if T4 and/or T3 were administered. Several
experimental paradigms were tested for acute or chronic 3,5-T2
formation from T4 and/or T3. Figure 5A shows the experimental
approaches used by Jonklaas et al. (53), who administered a
single dose of T3 (50 µg) to 12 euthyroid individuals and
sampled serum over 72 h. Assuming T3 as precursor of 3,5-
T2, one would expect an increase of 3,5-T2 concentration after
T3 administration. In a second paradigm (Figure 5B) (54),
T3 was administered at concentrations between 30 and 60
µg to hypothyroid patients, who at baseline were substituted
with T4. Their T4 was discontinued and they were instead
treated with a daily dose of 15 µg of T3. Subsequently the T3
dose was increased by 15, 30, or 45 µg to replace T4 over
a period of 4 weeks aiming for non-suppressed TSH. Blood
samples were drawn at baseline and then weekly during T3
treatment. Blood samples were also drawn hourly for 8 h after
the final T3 dose was given (Figure 5B). In a third paradigm,
we determined 3,5-T2 serum concentrations (data not shown)
TABLE 2 | Summary of serum 3,5-T2 concentrations in humans observed under
physiological (a) and pathophysiological (b) conditions.
a) Physiological conditions:
• Serum 3,5-T2 and 3T1AM concentrations as analyzed by specific mAb-based
CLIA do not mirror the dynamics of T3 (or T4) after substitution with T4, T3,
or T3-sulfate in healthy individuals or hypothyroid patients
• Inter-individual differences in 3,5-T2 and 3T1AM serum concentrations
• Remarkably stable individual 3,5-T2 and 3T1AM serum concentrations
• Discrepancy between 3,5-T2 serum concentrations determined by CLIA and
LC-MS/MS
• No clear correlation to TSH, T4, and T3 concentrations
• No evidence from these studies supporting the postulated metabolic pathway
in humans: T4→ T3→ 3,5-T2→ 3T1AM
• Serum 3,5-T2 concentrations are correlated to trigonelline, hippurate,
and 3-aminoisobutyrate concentration in urine of healthy individuals
(“coffee signature”).
b) Elevated serum concentrations of 3,5-T2 in patients:
• Sepsis
• Non-survivors of ICU
• Postoperative atrial fibrillation (POAF)
• Impaired renal function
• Oral T4 supplementation.
in 10 thyroidectomized patients who were treated with L-T4
or L-T3 to target their serum TSH to the reference range of
0.5–1.5 mU/L for at least 30 days, in order to test whether
T3 and T4 can lead to similar TSH concentrations in the
reference range (55). In the fourth study, 3,5-T2 concentrations
were determined (data also not shown) in sera of volunteers
receiving 100 µg of T3 sulfate, an endogenous THM, which
might act as reservoir or precursor to rapidly yield T3 liberated
by ubiquitous sulfatase enzymes (56). T3 sulfate is formed
during enterohepatic circulation of TH, and 3,3′-T2 sulfate is a
metabolite generated by the fetus and transferred to maternal
circulation during pregnancy (57, 58). Again, rapid formation
of T3 from T3 sulfate might lead to elevated production of
3,5-T2 if T3 and/or T3 sulfate would be precursors of 3,5-T2.
While analysis of T3 in serum for all four paradigms revealed the
expected kinetic profiles and TSH responses (53, 55, 56), the 3,5-
T2 concentration profiles found (Figure 5C) were unexpected.
In all of the above mentioned four paradigms, irrespective of
T4, T3, or T3 sulfate administration, significant changes of 3,5-
T2 serum concentration as determined by mAB-CLIA were not
observed [and also no changes in concentrations of 3-T1AM, also
determined bymonoclonal antibody CLIA (59), were found]. 3,5-
T2 had been postulated as a potential precursor of the biogenic
amine 3-iodo-thyronamine (3-T1AM), possibly enzymatically
generated from 3,5-T2 by a combination of deiodination and
decarboxylation (60, 61).
Together, these studies might indicate that 3,5-T2 is not
directly generated from serum T3 and its serum profile does
not mimic the transient increases observed for T3 after its
exogenous administration in humans. Several interpretations
can be put forward to explain this situation: (i) 3,5-T2
is not a direct product of T3, or (ii) increases in T3
or T3-sulfate concentration in serum are not reflected by
corresponding coincident or delayed 3,5-T2 concentration
profiles, (iii) but 3,5-T2 might be formed intracellularly in
Frontiers in Endocrinology | www.frontiersin.org 7 January 2020 | Volume 10 | Article 787
Köhrle et al. 3,5-T2—A Janus-Faced Thyroid Hormone Metabolite?
FIGURE 5 | Experimental paradigms to test whether 3,5-T2 is formed from T4/T3 in humans. (A) Twelve euthyroid healthy volunteers received a single oral dose of
L-T3 (50 µg) and blood samples were drawn during the following 72 h (53). (B) Eighteen hypothyroid patients were switched from T4 to daily doses of 15 µg
Liothyronine (T3) at week 1. Their daily T3 dose was then increased to 30 µg after week 2 and increased as necessary up to 60 µg T3 to maintain a normal serum
TSH. Serum samples were drawn weekly and also for a kinetic study during the 8 h after the final T3 dose was administered in week 6 (54). (C) Serum concentrations
(relative to individual concentrations at t = 0 h) for the two kinetic studies (see above) administering Liothyronine (T3) to euthyroid volunteers (upper panel) and
hypothyroid patients (lower panel). Individual serum concentration data are provided in Supplementary Data Sheet 1. No clear increase was found in serum 3.5-T2
concentration in both paradigms and also no increase was observed for 3-T1AM, the postulated product generated from 3,5-T2 via combined deiodination and
decarboxylation).
various tissues; (iv) the half-life of 3,5-T2 may be too
short to lead to accumulation of this metabolite in human
serum after T3, T3-sulfate1, or T4 administration; (v) the
monoclonal antibody-based immunoassay for 3,5-T2 may
recognize also additional cross-reacting compounds not formed
after in vivo application of T4, T3, or T3-sulfate. However,
these observed patterns in sera of these four studies do
contradict the above-mentioned observations that higher 3,5-
T2 concentrations were observed in thyroidectomized patients
on oral T4 replacement therapy (20, 62). Figure 5C shows
the serum profiles of 3,5-T2 found after T3 administration
in healthy controls and hypothyroid patients, respectively, in
the two Jonklaas studies (53, 54). Assay results had to be
normalized to time zero 3,5-T2 concentrations to generate
the kinetic profile. Of note are quite distinct individual 3,5-
T2 concentrations both in healthy individuals and hypothyroid
patients that were not affected by T3 administration, with
intra-individual 3,5-T2 serum concentrations that remained
remarkably stable during several hours and days of sampling
time (Figure 6).
3,5-T2 SERUM CONCENTRATIONS ARE
REMARKABLY STABLE AND DISTINCT
BETWEEN INDIVIDUALS
3,5-T2 concentrations in individuals exhibit remarkable stability
over sampling time. Figure 6 illustrates distribution of 3,5-T2
concentrations in various individuals over sampling time for
several hours and days. Figure 5C represents the analysis of 3,5-
T2 concentrations in healthy individuals (n = 12), to whom a
1Data are not shown for the 3,5-T2 serum profile after administration of T3 sulfate
or T4/T3 combination therapy.
single dose of 50 µg T3 was administered, and blood samples
were taken regularly over 72 h (53). Most individuals exhibit
very narrow concentration ranges with small variations over
sampling time while individuals differ among each other in their
3,5-T2 concentration in serum. Figure 5C also shows similarly
analyzed 3,5-T2 concentrations in 18 hypothyroid patients,
who received T3 doses between 30 and 60 µg total, following
discontinuation of T4 treatment (54). T3 was dosed to bring TSH
concentrations into the euthyroid reference range. Compared
to healthy individuals, inter-individual differences between 3,5-
T2 concentrations were more pronounced; nevertheless, each
individual again showed rather stable 3,5-T2 concentrations
over time, considering that, as illustrated above in Figure 6,
no significant changes in 3,5-T2 concentrations were observed
after T3 administration. Similar patterns of rather stable
individual 3,5-T2 concentrations were observed in a drug
study on volunteers, who underwent food withdrawal and
refeeding protocols while treated with an experimental drug
(J.K. et al., unpublished data). But again, explicit inter-individual
differences were observed between the volunteers, while 3,5-T2
concentrations remained fairly constant in each individual over
several circadian phases, food withdrawal and refeeding cycles,
and experimental drug administration. Only one individual was
exceptional in exhibiting rather pronounced variations of 3,5-
T2 for unknown reasons (unpublished data, van Vliet and
Köhrle). Unfortunately, no residual, sufficiently large serum
sample volumes (additional 200 µL) were available to repeat
those studies using the recently developed new LC-LIT-MS3
analysis of THM (25).
Taken together, the determination of 3,5-T2 concentrations
by mAb-based CLIA in experimental human studies involving
administration of T4, T3 alone, as well as T3 sulfate, or an
experimental drug did not provide evidence that the postulated
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FIGURE 6 | Remarkably stable individual 3,5-T2 serum concentrations during several hours and days of sampling time but significant inter-individual differences.
Graphs show absolute serum concentrations of 3,5-T2 (left) and 3-T1AM (right) for each individual receiving Liothyronine in the two kinetic studies presented in
Figures 5A,B. Upper panel (A): 12 euthyroid volunteers with blood drawn over 72 h; lower panel (B): 18 hypothyroid patients with blood drawn over 8 h.
Inter-individual differences for 3-T1AM serum concentrations seem to show higher variations than those for 3,5-T2, and variations over time might be more
pronounced than those of 3,5-T2. Individual serum concentration data are provided in Supplementary Data Sheet 2. Insets show typical standard curve for 3,5-T2
and 3-T1AM CLIA standard curves, with reference range marked in yellow. The red line represents the preliminary reference concentration for healthy controls.
metabolic pathway of T4→ T3→ 3,5-T2 deiodination could be
supported in analyses after short or medium-term interventions
in humans. Thus, it remains to be studied whether 3′(5′)-
deiodination of T3 to 3,5-T2 occurs in any human tissues and
can be measured in serum in healthy volunteer individuals or
hypothyroid patients requiring TH substitution.
ALTERNATIVE LC-MS-BASED
APPROACHES ARE NEEDED TO
DETERMINE CONCENTRATION OF
THYROID HORMONES AND THEIR
METABOLITES IN HUMAN SERUM
Over the last years, the discovery of various THM with either
lower iodination grade ormodifications at the functional residues
of iodothyronines, that is the 4′-hydroxy group conjugation or
modification of the alanine side chain, and subsequent studies
on the potential biological relevance of various THM (see
Graphical Abstract) has led to various attempts to quantify the
whole spectrum of iodinated and iodine-free metabolites [“the
thyronome” profile; (3)] using liquid chromatography—tandem
mass spectrometry (LC-MS/MS) techniques [for a recent review
see (23)]. Initial attempts to quantify T4 and its metabolites by
GC-MS did not gain acceptance for clinical diagnostics. The
MS-based analysis of THM is faced with several challenges:
(i) first of all, should total and/or free concentrations be
determined in whole blood, serum, plasma, or other body
fluids like saliva, cerebrospinal fluid, or urine? (ii) How can
THM be quantitatively analyzed considering their extremely
high affinity binding to various distributor proteins contained
in plasma, such as TBG, TTR, albumin, or APO-lipoprotein
B100? (iii) Which chromatographic procedure faithfully will
separate isobaric tri-, di-, or mono-iodinated structural isomers
of T4 metabolites? (iv) Is the sensitivity of combined LC-MS
sufficiently high to quantify in a single run nanomolar total
T4 and T3 concentrations and low picomolar concentrations of
mono- or di-iodinated THMs? (v) Which influence will matrix
composition of plasma or serum from healthy individuals vs.
sick patients exert, and can this be adequately standardized to
accurately quantify the concentrations of the THM spectrum
in clinical practice?
Appreciating the major progress made during the last
two decades in mass spectrometry-based analytics of steroid
hormones (63–66), several groups attempted to draw level
with those laboratories in the TH community also. However,
various practical and technical issues related to above-mentioned
challenges of TH physiology and pathophysiology hampered
rapid progress and success in quantification of total and free
THM concentrations. While meanwhile several laboratories
developed procedures to accurately determine total T4 and
total T3 in human plasma or serum and largely agree on
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concentrations ranges (25, 67–73), this consensus has not been
achieved yet for most of the other TH metabolites, which occur
at much lower concentrations. Analytical procedures typically
work well with buffer solutions, in vitro reaction mixtures, as
well as with samples of “simple” matrix composition, while
reported concentrations in human or experimental animal
serum, plasma, and tissue show wide variations and marked
insufficiencies in terms of method validation, standardization,
and quality assessment parameters [see (23, 24, 74)]. Most groups
reporting data employed liquid-liquid or solid-phase extraction
procedures with or without previous protein precipitation to
enrich and purify THM profiles from matrix components.
Nevertheless, sample recoveries, process efficiencies, and matrix
effects were not convincing in most of the cases published,
if reported at all. Although the teams used the principle of
isotope dilution technique, as far as isotope-labeled standards
for the individual thyronine metabolites are available, no
uniform picture has evolved yet. It has become apparent that
for accurate quantification of various THM, use of only one
or two stable isotope-labeled internal TH standards is not
sufficient due to the very distinct binding of THM, which are
highly hydrophobic but still polar amino acid derivatives. This
tight binding not only relates to their distribution proteins
in blood, cells or tissues but especially also to surfaces of
plastic material required during pre-analytical sample work and
subsequent MS quantification. Recently, two groups reported
for the first time 3,5-T2 serum concentrations determined by
LC-MS. Lorenzini et al. (75), observed a mean concentration
range for 3,5-T2 in human serum of 78 ± 9 pM, while our
own results (25) indicated that most human sera analyzed for
3,5-T2 have lower than 5 pM 3,5-T2 concentrations, which
is the lower limit of quantification in our method. The fact
that Lorenzini et al. probably report higher LC-MS-based 3,5-
T2 concentrations is due to the contamination of the 13C9-
15N-3,5-T2 internal standard, with “natural” unlabeled 3,5-
T2. While we used very high dilution of this internal isotope
labeled standard once we discovered this problem, Lorenzini
et al. who used the same supplier for this material, probably
included this “exogenously added 3,5-T2” in their analysis while
adding much higher undiluted internal standard concentrations
to their samples. A surprising outcome of both our own and the
Lorenzini study, however, is that MS-based analysis of 3,5-T2
concentration in sera of healthy individuals is significantly lower
than concentrations reported by our above-mentioned CLIA
based on monoclonal antibodies. At this point, no explanation
for the divergent results is possible yet, but needs to be considered
during future analysis and further improvement of analytical
methods for concentrations determination of 3,5-T2 in human
and animal serum (25). The method used by Richards et al.
involved a completely novel pre-analytical approach involving
single step solid-phase delipidation, avoiding multiple use of
plastic material during sample workup and employing silanized
glass vessels during this procedure. This sample work-up was
then combined with isotope dilution, LC-positive ion electron
spray multiple reaction monitoring (MRM) linear ion trap LIT-
MS3, which allowed clear separation of isobaric tri- and di-
iodinated iodothyronines and resulted in acceptable signal-noise
TABLE 3 | Ligand binding and cross reactivity of monoclonal antibodies used in
3,5-T2 and 3-T1AM CLIA as analyzed by immune extraction.
mAb 2H4-3-T1AM*
13C9-
15N-3,5-T*2 3,5-T2 T3 rT3 T4 3-T1-AM
(3-T1-AM)
(3,5-T2)
Ligand binding specificity and cross reactivity with other thyroid hormones/metabolites
was analyzed by immune extraction from native and spiked serum in parallel using
monoclonal antibodies (mAb) employed in the CLIA immune assays. Extracts bound to
the mAb were subsequently analyzed by LC-MS-MS. No significant cross reactivity for
the analytes indicated was detectable. *Stable-isotopically-labeled THM used as internal
standards in LC-MS/MS.
ratios for the LIT-MS3 scans leading to limits of quantification
in the low picomolar range. Assay accuracies, precisions, and
process efficiencies with quality assessment parameters were
obtained which are requested by authorities for analytical
procedures utilized in clinical diagnostics. Application of this
procedure allows for simultaneous, pre-analytical extraction
and mass-spectrometry quantification of T4, T3, rT3, 3,3′T2,
and 3,5-T2 in one single run using 200 µl serum (or less, if
the two di-iodinated thyroid hormones are not required for
these analytics). Major work is needed to clarify the differences
between mAb-based immunoassays and MS-based analytics.
Previously, other groups already reported major deviations
between immunoassay- and LC-MS-based methods, if T3, rT3,
or 3,3′T2 were analyzed in human serum (27, 76, 77). Application
of this new method for determination of free TH concentrations
will require significantly more work on method development
and quantification.
Using the monoclonal antibodies employed in the CLIA
methods, a series of immune extraction experiments from
native or spiked human serum was performed to clarify the
differences found in 3,5-T2 concentrations in human serum
using either the CLIA or LC-MS method (unpublished work).
Human serum aliquots were either used as prepared after blood
drawing or after spiking with analytes of interest. Aliquots
with known amounts of either 3,5-T2 or 3-T1AM sera were
incubated for equilibration at room temperature for 1 h, then
highly specific mAbs against 3,5-T2 (20) or 3-T1AM (59) were
added in form of beads covalently bound to these antibodies,
then sera were incubated overnight at 4◦C, serum was removed
by centrifugation, and antibody beads were recovered. Beads
were washed several times, and bound THM were eluted with
methanol and analyzed either by LC-MS/MS (25) or TOF-LC-
MS. Evaluation of extracts from mAb beads by LC-MS analysis
(25) revealed that the 3,5-T2 antibody efficiently extracted 3,5-T2
from serum as expected but did not bind and extract spiked 3-
T1AM or other endogenous THM. In contrast, the mAb against
3-T1AM, also coupled to beads, extracted spiked 3-T1AM from
serum, but no spiked 3,5-T2, no other THM and surprisingly not
any “endogenous” 3-T1AM was found in the extracted eluates
(Table 3) (J.K. et al., unpublished data). Careful analysis by TOF-
LC-MS did not provide information on significant enrichment
or extraction of any unknown serum components cross-reacting
either with the 3,5-T2 or the 3-T1AM mAbs to a measurable
extent. Thus, a carefully controlled immune-extraction approach
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of native or THM spiked serum did not reveal, why 3,5-T2
concentrations determined by mAB-based CLIA were so much
higher than those endogenous 3,5-T2 concentrations determined
by LIT-MS3 and the recently described one-step pre-analytical
extraction method.
3,5-T2 MECHANISM OF ACTION INVOLVES
CANONICAL TR SIGNALING AND RAPID
DIRECT EFFECTS
3,5-T2 Action on Liver Is Accompanied by
Potentially Adverse Effects on HPT-Axis
and Heart
3,5-T2, in contrast to its structural isomers 3,3′-T2 and 3′,5′-
T2, is an active ligand for the classical T3 receptors (TR),
where it binds with relative high affinity (Table 4) and modulates
transcriptional activity of TR, as indicated e.g., by rapid and
powerful suppression of TSH in vivo, altered 3,5-T2 modulated
gene expression in vitro and in several cellular models including
anterior pituitary and liver (39, 81, 85–87). In addition to its
action on TSH suppression in thyrotropes, 3,5-T2 also stimulates
growth hormone production and secretion in somatotrophs
(86). Apart from this work, elucidating thyromimetic effects
similar to those exerted by T3 in vivo as well as in various
experimental and cellular models, a group of researchers working
with Goglia et al. over the last three decades presented evidence
that 3,5-T2 might exert direct effects on mitochondria via
interaction with proteins of the electron transport chain (e.g.,
cytochrome C oxidase) and with F0-ATPase [for review see
(17)]. In addition to these actions, probably not mediated by
mechanism related to the canonical TR nor its mitochondrial
form, TRαp43 or TRαp22 (88), these authors claimed that 3,5-T2
might exert several beneficial actions on hepatic, muscular, and
adipocyte tissues already at “low” concentrations. In their models
apparently neither suppression of pituitary TSH production
and secretion nor T3-typical adverse effects on the heart were
observed at these doses used. Most of these studies were
performed in severely hypothyroid, mostly rat models, and
3,5-T2 doses were administered acutely as well as chronically.
Unfortunately, no information had been published on 3,5-T2
concentrations reached in the circulation or in those target
tissues like liver, where beneficial effects such as antisteatotic
activity and increased lipid metabolism were reported (15, 17,
28, 89, 90). The first evidence for rapid T3-independent effects of
3,5-T2 on mitochondrial activity and oxygen consumption was
provided by Horst et al. (16), who observed rapid stimulation of
oxygen consumption in isolated perfused livers, removed from
hypothyroid rats. In their model, already low picomolar 3,5-T2
concentrations stimulated O2 consumption within 90min, while
T4 and T3 reacted more slowly and their effect could be blocked
by adding 1µM PTU to the perfusion medium, which acts as
an inhibitor of DIO1, assumed to be the enzyme responsible for
3,5-T2 production. These authors studied several TH analogs
with respect to stimulation of oxygen consumption in their
model, in part complemented by analyses of stimulation of alpha-
glycerophosphate-dehydrogenase, which is a typical biomarker
TABLE 4 | Relative potencies of thyroid hormone metabolites at thyroid hormone
receptors expressed as fold concentration required to displace T3 from binding to
TRβ1 which is set as 1 (in bold) (corresponding to a Kd = 1 × 10
−10 nM).
Receptor T4 T3 rT3 3,5-T2 Tetrac Triac References
TRα1 14 2–20 – – – 3.9 (78)
TRβ1 3–22 1 300 – 33 3.6 (79, 80)
TRβ2 – 32 – 40–500 – 4.2 (81, 82)
pTRα28 – 3 – – – – (83)
Integrin ανβ3 3 – – – – – (84)
Published experimental data were obtained using various types of TH receptor
preparations, Scatchard analyses or competition assays, resulting in IC-50 values.
No systematic comparison was made using recombinantly expressed receptor under
comparable binding conditions, ad different tissues, and species were used in competition
experiments. Thus, only rough ranges are compiled here due to the limited comparability
of experimental models.
for TH action on mitochondria. Moreno et al. (90) performed
further studies on the time course and mechanisms involved
in rapid stimulation of resting metabolic rate caused by THM.
They observed that 3,5-T2 (25 µg/100 g body weight) exerted
rapid effects in acutely treated hypothyroid rats while T3 reacted
more slowly but with longer lasting effects compared to 3,5-
T2. The protein synthesis inhibitor actinomycin D inhibited
the effects of T3 similarly to observations made by Horst
et al. (16) who showed that cycloheximide could block the
T3 effect in their perfused liver model. Subsequently, the
Naples teams, with investigator Goglia, added more endpoints
to demonstrate rapid 3,5-T2 action, such as increased glucose
consumption in muscle, which might involve sirtuin signaling
(91). Several pathways involved in mediation of 3,5-T2 effects
were subsequently studied using gene expression, functional, and
proteomic readouts, especially for rat liver and muscle (92, 93)
while comparable control data on potentially adverse effects of
3,5-T2 concentrations resulting in changes of liver and muscle
metabolism were not systematically presented.
Controversial with respect to this set of observations,
several other teams reported that administration of 3,5-
T2 in rodent models (rat and mice, regular or high-fat
diet, euthyroid or hypothyroid) dose-dependently resulted in
significant suppression of the HPT axis as reflected by decreased
TSH serum concentrations and/or pituitary beta-TSH transcript
levels (6, 39, 87, 94, 95). Furthermore, thyromimetic effects
typical for high circulating T3 were observed in the heart as
analyzed by gene expression and/or morphological alterations
suspicious of remodeling and fibrosis. Typically, those changes
were then also accompanied by altered expression of T3
responsive genes in liver and other tissues. There have also
been observations that 3,5-T2 interferes with the function
of pancreatic islets altering glucagon and insulin expression
and secretion (91, 96). Thus, it remains quite controversial
whether 3,5-T2 would be an important lead compound in the
development of antisteatotic drugs lacking unwanted adverse side
effects at other TH responsive target tissues and reactions. The
Naples teams also reported a pilot volunteer study, where two
of the involved researchers dose escalated 3,5-T2 administration
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on themselves without observing unwanted side effects but
reported on weight loss (97). This observation could not be
supported by a randomized, placebo-controlled, double-blind,
4-week trial on male cardio-metabolic patients, who received a
50mg daily dose of TRC-150094 (98). This is a 3,5-T2 mimetic
agent previously shown to ameliorate metabolic risks in a high-
fat diet obese rat animal model, where oxidative metabolism was
significantly stimulated both in liver and skeletal muscle, and
several metabolic pathways such as nitrogen, amino acid and
sugar metabolism were shown to be altered using, among others,
proteome analysis (99). Different from this promising animal
experiment, the clinical trial provided no evidence for increased
insulin sensitivity, changes in plasma free fatty acids, or intra-
hepatic triglyceride content after administration of this agent
(98). No further studies are available on this agent in rodents
or humans.
3,5-T2 Accumulates in Tissues and Might
Act by Intracrine Mechanisms
The adverse effects observed in rodent hearts have not been
studied in more detail, and 3,5-T2 concentrations in cardiac
rodent tissue were found to be below detection limits (100)
in a study aiming to determine THM concentrations in rat
heart. Pinna et al. (29) determined 3,5-T2 concentrations based
on immunoassay under careful methodological precautions in
rat brains, and found quite high 3,5-T2 concentrations, which
differed among brain regions but were low in hypothalamus and
pituitary. In the study by Jonas et al. (39), who administered two
doses of 3,5-T2, only the higher one led to antisteatotic effects
in the liver while both suppressed the HPT axis. That effect
of 3,5-T2 on hepatic metabolism, especially lipid metabolism,
might be due to a remarkable accumulation of 3,5-T2 in the liver,
which so far had not been reported in appropriate experimental
paradigms. Whether 3,5-T2 accumulation is an issue of increased
import or decreased export remains to be studied, as the classical
transporters for thyroid hormones such as MCT8, MCT10,
OATP, and LATs typically show low transport activity for 3,5-T2
compared to the other T4, T3, or 3,3′-T2, as the structural isomer
of 3,5-T2 (101, 102). Considering these controversial and—with
respect to species analyzed and models employed—conflictings
observations, the initial enthusiasm of developing 3,5-T2 related
agents as anti-steatotic drugs, devoid of thyromimetic activity
and side effects, remains questionable, and more research is
definitely needed if this path should be further taken. The
available data sets also strongly discourage use of 3,5-T2, highly
popular in the body-building and wellness scene and freely
available via the internet, as a sliming or energy-boosting drug.
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Supplmentary Data Sheet 1 | Serum concentrations of 3,5-T2 and 3-T1AM
(relative to individual concentrations at t = 0 h) for the two kinetic studies
administering Liothyronine (T3) to euthyroid volunteers (Figure 5C, upper panel)
and hypothyroid patients (Figure 5C, lower panel).
Supplmentary Data Sheet 2 | Serum concentrations of 3,5-T2 and 3-T1AM for
each individual receiving Liothyronine in the two kinetic studies presented in
Figure 6. Upper panel (A): 12 euthyroid volunteers with blood drawn over 72 h;
lower panel (B): 18 hypothyroid patients with blood drawn over 8 h.
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